Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Earnings analysis
Keenova Therapeutics plc · Third quarter 2026

Keenova's Acthar and XIAFLEX lift guidance, but the quarter still ends in a $96M loss

Third-quarter net sales from continuing operations reached $550 million and full-year targets rose, yet a Percocet divestiture loss kept Keenova in the red.

15 Nov 2026 · CompePharma editorial
$550 millionNet sales, continuing operations
$227 million (+25%)Acthar Gel net sales
$164 millionXIAFLEX net sales
$96 million (vs $242 million)Loss from continuing operations
$233 millionAdjusted EBITDA, continuing operations
$750M to $770MNew FY 2026 pro forma Adjusted EBITDA guidance

The quarter in numbers

Keenova Therapeutics, formerly Mallinckrodt, reported net sales from continuing operations of $550 million for the quarter ended September 30, 2026. That is $133 million above the same period of 2025, which implies a prior-year base of about $417 million. Loss from continuing operations narrowed to $96 million from $242 million. Adjusted EBITDA from continuing operations was $233 million, or roughly 42% of net sales on our arithmetic.

The company did not give a prior-year Adjusted EBITDA figure in the release text provided, so the year-over-year trend in the non-GAAP measure cannot be read from it. The company also changed its Adjusted EBITDA definition in the second quarter of 2026 to add an adjustment for strategic initiative costs, and said it recast prior periods. Comparisons with earlier reports should account for that.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.

More CP+ Earnings analysisAll →
CP+ Earnings analysis
CorMedix Inc. · CRMD · Third quarter 2026

CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook

$54.5 millionQ3 2026 consolidated revenue$17.2 millionDefenCath net revenue$14.7 millionQ3 2026 net loss

Consolidated revenue of $54.5M beat the consensus the company cited, but DefenCath pricing, a $3.1M adjusted EBITDA and suspended 2027 guidance leave Heron and REZZAYO carrying the story.

17 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Iambic Therapeutics, Inc. · IAM · Third quarter 2026

Iambic's Q3: AI-platform deals double revenue, but the clinic drives the burn

$11.4 million (vs $4.7 million in Q3 2025)Q3 2026 collaboration revenue$34.1 million (vs $23.1 million)Q3 2026 R&D expenses$38.5 million (vs $21.5 million)Q3 2026 net loss

Collaboration revenue rose to $11.4M and pro forma cash reached about $455M after the IPO, while R&D and G&A spending climbed as Iambic moves three oncology assets toward and into the clinic.

16 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Alumis Inc. · ALMS · Third quarter 2026

Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib's path

$1.9 million (vs $2.1 million in Q3 2025)Q3 2026 collaboration revenue$80.8 million (vs $97.8 million)Q3 2026 R&D expenses$94.9 million (vs $110.8 million)Q3 2026 net loss

Lower R&D cut the quarterly net loss to $94.9M, with a psoriasis NDA still due in 4Q 2026 and cash guided into 4Q 2027, while the LUMUS Phase 2b missed in the overall population.

16 Nov 2026 · CompePharma editorial